Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Investigative Directions in Ovarian Cancer Continue to Comprise Multidisciplinary Approaches

August 27th 2021

Sanaz Memarzadeh, MD, PhD, focuses on these ongoing multidisciplinary research directions aimed at improving outcomes for patients with ovarian cancer.

Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian Cancer

August 24th 2021

Rachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.

Dr. Willmott on Expanding Genomic Testing in Ovarian Cancer

August 19th 2021

Lyndsay Willmott, MD, discusses the expanding role for genomic testing in ovarian cancer.

Dr. Monk on the Utility of PARP Inhibitors as Frontline Maintenance in Ovarian Cancer

August 19th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as frontline maintenance therapy in ovarian cancer.

Dr. Grisham on the Rationale for Binimetinib in Low-Grade Serous Ovarian Cancer

August 19th 2021

Rachel N. Grisham, MD, discusses rationale for evaluating binimetinib as a treatment option for patients with low-grade serous ovarian cancer.

Dr. O’Malley on the Utility of Chemoimmunotherapy in Ovarian Cancer

August 16th 2021

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dr. Chase on the Importance of Genetic Testing for BRCA Mutations in Ovarian Cancer

August 12th 2021

Dana Chase, MD, FACOG, gynecologic oncologist, discusses the importance of utilizing genetic testing for BRCA mutations in ovarian cancer.

Niraparib Maintains Safety, Efficacy in BRCA+ Ovarian Cancer, Irrespective of Setting

August 12th 2021

Maintenance niraparib has been shown to result in a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer following response to platinum-based chemotherapy.

Maveropepimut-S Demonstrates Encouraging Activity in Recurrent Ovarian Cancer

August 10th 2021

The subcutaneously administered peptide cancer vaccine maveropepimut-S was found to produce promising activity in heavily pretreated patients with recurrent ovarian cancer.

Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer

August 9th 2021

Lyndsay Willmott, MD, discusses the importance of genetic testing in ovarian cancer.

GEN-1 Plus Neoadjuvant Chemo Appears Active, Safe in Advanced Ovarian Cancer

August 8th 2021

The addition of GEN-1 to standard-of-care neoadjuvant chemotherapy has shown preliminary safety and clinical activity and appears to have an impact on the tumor microenvironment in patients with advanced epithelial ovarian cancer.

Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers

July 29th 2021

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Adavosertib, With or Without Olaparib, Showed Promising Efficacy in PARP-Resistant Ovarian Cancer

July 20th 2021

Shannon Westin, MD, MPH, discusses the key takeaways from the EFFORT trial, future research directions with adavosertib, and the characteristics of PARP inhibitor resistance in patients with ovarian cancer.

Immunotherapy GEN-1 Demonstrates Acceptable Risk/Benefit Profile in Advanced Ovarian Cancer

July 20th 2021

The novel gene-mediated immunotherapy GEN-1 showcased satisfactory safety with an acceptable risk/benefit profile when given over a 6-month period with up to 17 doses in newly diagnosed patients with stage III/IV ovarian cancer.

Persistent Development of WEE1 Pathway Inhibitors Begins to Pay Off

July 16th 2021

The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.

Ceralasertib/Olaparib Combo Elicits Promising Activity in PARP-Resistant Ovarian Cancer

July 15th 2021

The combination of ceralasertib and olaparib induced clinical activity and was well tolerated in patients with homologous recombination deficient, recurrent platinum-sensitive, PARP inhibitor–resistant ovarian cancer.

Dr. O’Malley on the Promise of Antibody-Drug Conjugates in Ovarian Cancer

July 14th 2021

David M. O'Malley, MD, discusses the promise of antibody-drug conjugates in ovarian cancer.

Dr. Miller on the Safety, Efficacy of Veliparib Vs Other PARP Inhibitors in Ovarian Cancer

July 14th 2021

Eirwen M. Miller, MD, discusses the safety and efficacy of veliparib vs other PARP inhibitors used in the treatment of patients with ovarian cancer.

Dr. Chern on Outcomes With PARP Inhibitors in Recurrent Ovarian Cancer

July 14th 2021

Jing-Yi Chern, MD, ScM, discusses outcomes with PARP inhibitors in patients with recurrent ovarian cancer.